A HUMAN LYMPHOID RECOMBINANT CELL-LINE WITH FUNCTIONAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE
A HUMAN LYMPHOID RECOMBINANT CELL-LINE WITH FUNCTIONAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE
复制标题
DOI：
10.1089/aid.1993.9.23
复制
发表时间：
1993-01-01
影响因子：
1.5
通讯作者：
DEBOUCK, C
中科院分区：
文献类型：
--
作者：
JONAK, ZL;CLARK, RK;DEBOUCK, C
我们的目标是开发一种安全有效的系统，使我们能够探索人类免疫缺陷病毒（HIV）包膜的功能。我们已经产生了一个人淋巴样细胞系（TF228.1.16），稳定表达功能性HIV包膜蛋白在其细胞表面，因此密切模仿病毒包膜和病毒感染的细胞。TF 228.1.16细胞系与CD4+表型的人细胞形成合胞体，并提供了一种简便的无病毒细胞测定法，用于检查合胞体形成的机制和评价可能破坏该过程的新型药物。TF228.1.16细胞还提供了将HIV包膜蛋白以细胞形式呈递给免疫系统的机会。人外周血单核细胞（PBMC）的体外免疫和恒河猴的体内免疫可产生具有中和（抗合胞体）活性的抗体。当HIV包膜在人类淋巴样细胞的背景下表达时，它可能表现出具有尚未探索的独特性质的免疫保护作用。我们的研究结果表明，无病毒的细胞系统可以发挥重要作用，在探索HIV包膜蛋白的生物学和功能，而不干扰感染细胞中存在的其他病毒成分。本文讨论了这些结果，并探讨了TF228.1.16作为疫苗的潜在用途。
Our goal has been to develop a safe and effective system that would allow us to explore the functions of the human immunodeficiency virus (HIV) envelope. We have generated a human lymphoid cell line (TF228.1.16) that stably expresses functional HIV envelope proteins on its cell surface, and therefore closely mimics the viral envelope and virus-infected cells. The TF228.1.16 line forms syncytia with human cells of the CD4+ phenotype and provides a facile virus-free cell-based assay for examining the mechanism of syncytia formation and for evaluating novel agents that may disrupt this process. The TF228.1.16 cells also provide an opportunity to present the HIV envelope proteins to the immune system in cellular form. In vitro immunization of human peripheral blood mononuclear cells (PBMC) and in vivo immunization of rhesus monkeys with this reagent results in the production of antibodies with neutralizing (anti-syncytia) activities. When the HIV envelope is expressed against the background of human lymphoid cells, it may exhibit immune protection with unique properties that have not yet been explored. Our results indicate that a virus-free cell system can play an important role in exploring the biology and function of HIV-envelope proteins without the interference of other viral components present in infected cells. This paper discusses these results, and examines the potential use of TF228.1.16 as a vaccine.